IONS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ionis Pharmaceuticals Inc (IONS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong institutional interest, positive analyst sentiment, and potential catalysts in 2026. Despite some financial challenges, the company's growth prospects and upcoming earnings report make it an attractive investment.
The technical indicators show mixed signals. The MACD is negative and expanding (-0.065), suggesting bearish momentum. RSI is neutral at 37.485, while moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The current price is near the S1 support level (81.881), indicating a potential buying opportunity.
Hedge funds are significantly increasing their holdings (242.57% increase in buying).
Analysts have raised price targets, with targets ranging from $87 to $100, and maintain Overweight/Buy ratings.
Upcoming earnings report on February 18, 2026, with potential catalysts from Phase 3 readouts in
Strong industry outlook for biotech in 2026, with potential mergers and acquisitions.
Financial performance shows a decline in net income (-8.45% YoY) and EPS (-15.79% YoY) in Q3
Gross margin dropped slightly (-0.70% YoY).
Lack of recent news or congress trading data to provide additional confidence.
In Q3 2025, revenue increased by 17.12% YoY to $156.72M, showing growth. However, net income dropped by 8.45% YoY to -$128.61M, and EPS declined by 15.79% YoY to -0.8. Gross margin remains high at 98.51%, though it decreased slightly (-0.70% YoY).
Analysts are highly positive on IONS, with multiple firms raising price targets recently. Piper Sandler raised the target to $87, Barclays to $95, Wells Fargo to $100, RBC Capital to $95, and BofA to $97. All firms maintain Overweight/Buy ratings, citing strong fundamentals, upcoming catalysts, and undervaluation in the biotech sector.
